Immuron Ltd
Immuron Ltd (IMRN): 1 pipeline candidate · 1 clinical trial. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E 0.26 · 0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for Immuron Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$8.5M
Cash
$2.8M
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| travelan | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
7
Total value held
$66K
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 30,574 | $24K |
| xtx topco ltd | 17,383 | $13K |
| citadel advisors llc | 13,804 | $11K |
| two sigma securities, llc | 10,906 | $8K |
| rhumbline advisers | 7,367 | $6K |
| bnp paribas financial markets | 4,600 | $4K |
| blackrock, inc. | 225 | $174 |
Frequently asked questions
How many drug candidates are in Immuron Ltd's pipeline?
Immuron Ltd (IMRN) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Immuron Ltd's lead drug candidate?
Immuron Ltd's most advanced tracked candidate is travelan (Phase 2) for Diarrhea.
What is Immuron Ltd's market capitalization?
Immuron Ltd's market capitalization is approximately $8.5M.
Who is the CEO of Immuron Ltd?
Mr. Steven George Lydeamore CPA, M.B.A. is the chief executive officer of Immuron Ltd (IMRN).
Get the full picture on Immuron Ltd
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.